Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic polymorphisms in emerging cardiovascular risk factors and response to statin therapy.

Cardiovascular drugs and therapy - 1 Jan 2003

Dornbrook-Lavender Kimberly A, Pieper John A

Abstract excerpt

Current strategies for both the primary and secondary prevention of coronary heart disease (CHD) focus on the traditional risk factors, such as hypertension, smoking cessation, and cholesterol, as the primary determinants of the cardiac risk profile, with particular emphasis on the reduction of low-density lipoprotein cholesterol (LDL-C) to targeted goal levels as endorsed by the National Cholesterol Education...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholesterol, LDL
Share to Clinical Trials as Topic
Share to Coronary Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Markers

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hypercholesterolemia

Share to Polymorphism, Genetic

Share to Risk Factors

Source

Identifiers

PMID: 12843689
DOI: 10.1023/a:1024212026578

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic polymorphisms in emerging cardiovascular risk factors and response to statin therapy.PMID 12843689Read ↗

Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors.Semantic proximity Read ↗

When the same treatment has different response: The role of pharmacogenomics in statin therapySemantic proximity Read ↗

Towards a More Personalized Treatment of Dyslipidemias to Prevent Cardiovascular Disease.Semantic proximity Read ↗

Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for DyslipidemiaSemantic proximity Read ↗

Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart DiseaseSemantic proximity Read ↗

Pharmacogenomics of cholesterol-lowering therapy.Semantic proximity Read ↗

Association between selected gene polymorphisms and statin metabolism, risk of ischemic stroke and cardiovascular disorders.Semantic proximity Read ↗

Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease managementSemantic proximity Read ↗

Statin response and pharmacokinetics variants.Semantic proximity Read ↗

Genomic Variations Affecting Biological Effects of Statins.Semantic proximity Read ↗

Relationship between Apolipoprotein E Genotype and Lipoprotein Profile in Patients with Coronary Heart Disease.Semantic proximity Read ↗

Cardiovascular disease genetics: a long and winding road.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.